JPMorgan Chase & Co. Acquires 189,665 Shares of LivaNova PLC (NASDAQ:LIVN)

JPMorgan Chase & Co. raised its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 95.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 387,772 shares of the company's stock after purchasing an additional 189,665 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.71% of LivaNova worth $17,958,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Central Pacific Bank Trust Division raised its position in shares of LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after acquiring an additional 720 shares during the period. Captrust Financial Advisors acquired a new stake in LivaNova in the 3rd quarter valued at $217,000. Sanctuary Advisors LLC bought a new stake in LivaNova during the third quarter worth about $219,000. Vestcor Inc acquired a new position in LivaNova during the fourth quarter worth $204,000. Finally, Inceptionr LLC bought a new stake in shares of LivaNova in the 4th quarter valued at about $217,000. Institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LIVN. The Goldman Sachs Group lowered their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research note on Monday, March 17th. Mizuho dropped their price objective on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus lowered their price objective on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Finally, StockNews.com raised LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, March 25th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, LivaNova has a consensus rating of "Buy" and a consensus target price of $61.17.

LivaNova Trading Up 0.4 %

Shares of LIVN traded up $0.14 during mid-day trading on Thursday, reaching $35.21. The company's stock had a trading volume of 135,025 shares, compared to its average volume of 677,604. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $64.47. The company's fifty day moving average price is $40.59 and its two-hundred day moving average price is $47.00. The stock has a market cap of $1.91 billion, a PE ratio of 83.83 and a beta of 0.90.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.